Gemphire Therapeutics Inc. 4
4 · Gemphire Therapeutics Inc. · Filed Mar 14, 2017
Insider Transaction Report
Form 4
Hawryluk P. Kent
Director
Transactions
- Purchase
Common Stock
2017-03-10$9.47/sh+25,000$236,750→ 81,889 total(indirect: By Trust) - Purchase
Warrant to Purchase Common Stock
2017-03-10$9.47/sh+18,750$177,563→ 18,750 total(indirect: By Trust)Exercise: $10.40From: 2017-03-10Exp: 2022-03-15→ Common Stock (18,750 underlying)
Holdings
- 32,062
Common Stock
Footnotes (2)
- [F1]The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017.
- [F2]These shares are indirectly owned by the reporting person as trustee of the P. Kent Hawryluk Revocable Trust.